Acadia Pharma (ACAD) Halted Ahead of FDA PDAC Review of NUPLAZID
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
ACADIA Pharmaceuticals Stock Trading Halted Today
March 29, 2016 7:05 AM EDTFDA Advisory Committee to Review NUPLAZID (Pimavanserin) New Drug Application for the Treatment of Parkinsons Disease Psychosis
SAN DIEGO--(BUSINESS WIRE)-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system (CNS) disorders, today announced that NASDAQ has halted trading of the companys common stock.
The U.S. Food and Drug Administration (FDA) Psychopharmacologic Drugs Advisory Committee (PDAC) is meeting today to review NUPLAZID (pimavanserin) for the treatment of patients... More
